A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer

Trial Profile

A Randomized Phase II Trial Evaluating the Endocrine Activity and Efficacy of Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Receiving Letrozole for Primary Endocrine Responsive Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Degarelix (Primary) ; Letrozole; Triptorelin
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Acronyms TREND
  • Most Recent Events

    • 12 Dec 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Mar 2018.
    • 09 Dec 2017 Results of preliminary analysis (n=45) presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top